Developing kinase inhibitors poses several challenges:
- Selectivity: Given the large number of kinases in the human genome, achieving selectivity to target only the dysregulated kinase without affecting others is challenging. - Resistance: Cancer cells can develop resistance to kinase inhibitors through mutations in the kinase or activation of alternative pathways. - Toxicity: Inhibitors may have off-target effects that cause toxicity in patients.
